Utilization of Oncotype DX to predict chemotherapy use in an inner-city population.

Guth, Amber; Fineberg, Susan; Fei, K.; Franco, Renato; Bickell, Nina A.

doi:10.1200/jco.2011.29.15_suppl.e11131

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariable analysis indicated that patients with lower tumor stages, lower grade, negative lymph node status, negative HER2 status, and of Caucasian descent were all significantly more likely to be an Oncotype DX user compared to non-users (Table 1 ). Discrepancies in Oncotype DX testing rate between different races have indeed been observed in previous studies [ 20 , 28 ]. Oncotype DX users were also less likely to have received chemotherapy, but they were more likely to have received radiation therapy compared to non-Oncotype DX users.…”

Section: Resultssupporting

confidence: 69%

“…The Oncotype DX assay has been used widely to predict the recurrence risk of breast cancer after surgical resection in ER+HER2− breast cancer [11]. Based on the expression levels of 21 genes, the test calculates a risk recurrence score from 0 to 100 that stratifies patients into three groups: high-(≥ 31), intermediate- (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30), and low-risk (0-17) of recurrence. The Oncotype DX test has been endorsed by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) [11,12].…”

Section: Introductionmentioning

confidence: 99%

“…Consistently, patients with low-risk Oncotype DX scores do not benefit from the additional chemotherapy and are consequently rarely treated with chemotherapy [16][17][18][19]. On the contrary, the usage of chemotherapy is reported highest among patients with an Oncotype DX score ≥ 31 (high risk of recurrence) compared to lower Oncotype DX scores [16,[19][20][21]. High-risk patients identified by the Oncotype DX assay are more likely to benefit from chemotherapy than low-risk patients in both neoadjuvant and adjuvant treatment regimens [22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

et al. 2021

View full text Add to dashboard Cite

Background The Oncotype DX breast recurrence score has been introduced more than a decade ago to aid physicians in determining the need for systemic adjuvant chemotherapy in patients with early-stage, estrogen receptor (ER)+, lymph node-negative breast cancer. Methods In this study, we utilized data from The Surveillance, Epidemiology, and End Results (SEER) Program to investigate temporal trends in Oncotype DX usage among US breast cancer patients in the first decade after the introduction of the Oncotype DX assay. Results We found that the use of Oncotype DX has steadily increased in the first decade of use and that this increase is associated with a decreased usage of chemotherapy. Patients who utilized the Oncotype DX test tended to have improved survival compared to patients who did not use the assay even after adjusting for clinical variables associated with prognosis. In addition, chemotherapy usage in patients with high-risk scores is associated with significantly longer overall and breast cancer-specific survival compared to high-risk patients who did not receive chemotherapy. On the contrary, patients with low-risk scores who were treated with chemotherapy tended to have shorter overall survival compared to low-risk patients who forwent chemotherapy. Conclusion We have provided a comprehensive temporal overview of the use of Oncotype DX in breast cancer patients in the first decade after Oncotype DX was introduced. Our results suggest that the use of Oncotype DX is increasing in ER+ breast cancer and that the Oncotype DX test results provide valuable information for patient treatment and prognosis.

show abstract

Section: Resultssupporting

confidence: 69%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To date, much of the research on Onco type Dx results' association with treatment decision-making has occurred in an academic setting. Some research conducted with an inner-city population suggests that Onco type Dx results may influence chemotherapy treatment decisions in this setting [ 19 ]. In this sample of 47 women who underwent Onco type Dx testing, 5% of women with a low RS and 100% of women with a high RS received chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting

Malo

Lipkus

Wilson

et al. 2012

Journal of Cancer Epidemiology

View full text Add to dashboard Cite

Introduction. This study aimed to evaluate whether OncotypeDx test results predict receipt of adjuvant chemotherapy in breast cancer patients who received an OncotypeDx recurrence score (RS). Materials and Methods. Pathology records were used to identify breast cancer patients who had OncotypeDx testing between December 2004 and January 2009 (n = 118). Patient sociodemographic information, tumor characteristics, RS, and treatment-specific data were collected via chart review. RS was classified as follows: low (RS ≤ 17), intermediate (RS = 18–30), or high (RS ≥ 31). Bivariate analyses were conducted to investigate the relationship between adjuvant chemotherapy receipt and each sociodemographic and clinical characteristic; significant sociodemographic and clinical variables were included in a multivariable logistic regression model. Results. In multivariable analysis controlling for tumor size, histologic grade, and nuclear grade, only RS remained significantly associated with chemotherapy uptake. Relative to low RS, an intermediate (adjusted odds ratio [AOR], 21.24; 95% confidence interval [CI], 3.62–237.52) or high (AOR, 15.07; 95% CI, 1.28–288.21) RS was associated with a greater odds of chemotherapy uptake. Discussion. Results indicate that RS was significantly associated with adjuvant chemotherapy uptake, suggesting that OncotypeDx results were used to inform treatment decision making, although it is unclear if and how the information was conveyed to patients.

show abstract

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Carlson

Roth

2013

Breast Cancer Res Treat

191

View full text Add to dashboard Cite

The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT) treatment decisions has been evaluated in many previous studies. However, it can be difficult to interpret the collective findings, which were conducted in diverse settings with limited sample sizes. We conducted a systematic review and meta-analysis to synthesize the results and provide insights about ODX utility. Studies, identified from PubMed, Embase, ASCO, and SABCS, were included if patients had ER+, node –, early-stage breast cancer, reported use of ODX to inform actual ACT decisions. Information was summarized and pooled according to: (1) distribution of ODX recurrence scores (RS), (2) impact of ODX on ACT recommendations, (3) impact of ODX on ACT use, and (4) proportion of patients following the treatment suggested by the ODX RS. A total of 23 studies met inclusion criteria. The distribution of RS categories was 48.8 % low, 39.0 % intermediate, and 12.2 % high (21 studies, 4,156 patients). ODX changed the clinical-pathological ACT recommendation in 33.4 % of patients (8 studies, 1,437 patients). In patients receiving ODX, receipt of ACT were: 28.2 % overall, 5.8 % low, 37.4 % intermediate, and 83.4 % high. High RS patients were significantly more likely to follow the treatment suggested by ODX versus low RS patients RR: 1.07 (1.01–1.14). The pooled results are consistent with most individual studies to date. The increased proportion of intermediate scores relative to original estimates may have implications for the clinical utility and cost impacts of testing. In addition, low versus high RS patients were significantly more likely to follow the ODX results, suggesting a tendency toward less aggressive treatment, despite a high ODX RS. Finally, there was a lack of studies on the impact of ODX on ACT use versus standard approaches, suggesting that additional studies are warranted.

show abstract

Utilization of Oncotype DX to predict chemotherapy use in an inner-city population.

Cited by 3 publications

References 0 publications

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Contact Info

Product

Resources

About